Q-omics provides the consensus-scored NT5C2 profile across patient tissues and cancer cell-line models. NT5C2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NT5C2 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, NT5C2 RNA expression shows 20,649 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where NT5C2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NT5C2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NT5C2 survival associations across molecular data types. NT5C2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NT5C2 RNA expression–survival associations across cancer types. High NT5C2 expression shows unfavorable associations in SCLC, but favorable associations in KIRC, HNSC, UCS, LGG and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NT5C2 RNA expression.
This table summarizes NT5C2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for NT5C2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NT5C2 shows lower tumor expression in THCA, KIRC, KICH and HNSC and higher tumor expression in CHOL and LUAD. The THCA box plot shows higher NT5C2 RNA expression in normal versus tumor tissue (log2 FC = −1.072, t-test p < 0.001).
This table shows molecular features associated with NT5C2 in patient tissues and cancer cell lines. In patient samples, NT5C2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NT5C2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
